Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.php

Latest From CSPC Pharmaceutical Group Limited

Fewer Biotech-Pharma M&As But Tie-ups Indicate New China Trends

The past year witnessed only one major acquisition of a Chinese biotech by a major pharma company. However, some established firms such as Hansoh have set a new course for collaboration with much smaller peers by in-licensing preclinical assets.

China Deals

Astellas Reports Second Phase III Win With Zolbetuximab In Stomach Cancer

The anti-Claudin-18.2 agent plus chemotherapy improves progression-free survival in inoperable or metastatic stomach cancer, following a similar Phase III readout in November.

Clinical Trials Business Strategies

Drugs In Short Supply As China Hunkers Down For COVID Surge

As citizens in China grapple with the virtual end of pandemic restrictions and rush for medicines from cold remedies to traditional options, even some prescription antivirals such as Paxlovid are appearing online, while cheaper but unauthorized Indian generic versions have quickly sold out. Meanwhile, a renewed vaccination effort is targeting high-risk individuals and second booster shots as the country faces a huge surge in cases.

China Coronavirus COVID-19

Chinese Pharma Looks To Out-Licensing As Domestic Downturn Bites

China's biopharma firms including Hengrui Medicine and HUTCHMED actively pursue licensing partners for their drug assets as the economic downturn caused by domestic COVID flare-ups continues worsening. Meanwhile, there are some predictions that smaller biotechs in the country may need to tap into multinationals' deep pockets to raise new funds.

China Deals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    • NovaRock Biotherapeutics, Shijiazhuang Pharma Group
    • China Shijiazhuang Pharmaceutical Group Co Ltd
    • Hong Kong Tainuo Pharma Ltd
    • Jiangsu Tainuo Pharmaceutical Co Ltd
    • CSPC Pharmaceutical Group Co., Ltd.
    • JMT-Bio
    • Shanghai Jinmante Biotechnology Co., Ltd.
UsernamePublicRestriction

Register